Marathon Capital Management Grows Holdings in ADMA Biologics Inc $ADMA

Marathon Capital Management increased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 82.9% in the second quarter, HoldingsChannel.com reports. The firm owned 283,690 shares of the biotechnology company’s stock after buying an additional 128,570 shares during the period. ADMA Biologics accounts for approximately 1.3% of Marathon Capital Management’s portfolio, making the stock its 22nd largest holding. Marathon Capital Management’s holdings in ADMA Biologics were worth $5,166,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Amalgamated Bank lifted its stake in ADMA Biologics by 0.8% during the second quarter. Amalgamated Bank now owns 67,665 shares of the biotechnology company’s stock worth $1,232,000 after purchasing an additional 540 shares in the last quarter. New York State Teachers Retirement System grew its position in ADMA Biologics by 0.3% in the 2nd quarter. New York State Teachers Retirement System now owns 222,461 shares of the biotechnology company’s stock valued at $4,051,000 after acquiring an additional 571 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of ADMA Biologics by 3.9% during the second quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 629 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of ADMA Biologics by 1.3% in the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock valued at $1,002,000 after purchasing an additional 670 shares during the period. Finally, Cerity Partners LLC boosted its stake in shares of ADMA Biologics by 1.8% in the second quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock valued at $884,000 after purchasing an additional 869 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Up 0.9%

Shares of ADMA Biologics stock opened at $19.98 on Thursday. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The company has a 50 day moving average of $16.25 and a 200 day moving average of $17.27. The company has a market capitalization of $4.76 billion, a P/E ratio of 23.23 and a beta of 0.43. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The company had revenue of $134.22 million for the quarter, compared to analysts’ expectations of $131.20 million. During the same period last year, the firm earned $0.15 earnings per share. ADMA Biologics’s quarterly revenue was up 12.0% on a year-over-year basis. As a group, research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $28.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.